Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06927050 · ClinicalTrials.gov registry record · NA
Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers
A NA study of Cancer, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT06927050: Recruiting NA study of Cancer, sponsored by NYU Langone Health.
NCT06927050 is a NA study of Cancer that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 86 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06927050, a NA study of Cancer, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.
Primary Outcome
Patients will take a 9-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; patients with 6 or more "Yes" answers out of 9 questions are defined as "Satisfied" patients.
Conditions Studied
Interventions
- BEHAVIORAL Visual Communication Tool
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2026-04-01 |
| Phase | NA |
What NCT06927050 shows while recruiting
NCT06927050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Visual Communication Tool is the first listed.
NCT06927050 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06927050 about?
NCT06927050 is a clinical study titled "Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers". This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.
What is the current status of trial NCT06927050?
This trial is currently recruiting. It is a NA study. The enrollment target is 86 participants. The study started on 2025-04-21. Estimated completion is 2026-04-01.
What conditions does trial NCT06927050 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT06927050?
The interventions under investigation include: Visual Communication Tool (BEHAVIORAL).
Who is sponsoring clinical trial NCT06927050?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06927050 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06927050's enrollment target sits among peer trials
86 342nd of 615 higher than 273 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI